Chembio Diagnostics launches COVID-19 serologic point-of-care test
Chembio Diagnostics, a point-of-care diagnostic company focused on infectious diseases, launched a rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies.
Test results can be obtained within 15 minutes from a simple finger stick using Chembio’s MicroReader 1 and MicroReader 2 analyzers.
The DPP COVID-19 test detects antibodies in the blood that are produced by the body in response to a novel coronavirus infection. The numerical readings of the IgM and IgG antibodies help clinicians determine if patients have been exposed to the novel coronavirus, even among patients who exhibit mild to no symptoms, the company said.
Detection of an acute infection phase, as determined by the level of IgM antibodies, helps determine if a patient may still be infectious and could possibility transmit the infection to another person. Further along in the infection progression, the body typically starts to produce IgG antibodies, which increase while IgM levels decrease until eventually only IgG antibodies are present, demonstrating prior infection without the ability to transmit the virus.
